Cargando…
Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study
NF-κB signaling promotes cancer progression in a large number of malignancies. Metadherin, a coactivator of the NF-κB transcription complex, was recently identified to regulate different signaling pathways that are closely related to cancer. We assessed the immunohistochemical expression of p50, p65...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055019/ https://www.ncbi.nlm.nih.gov/pubmed/24963474 http://dx.doi.org/10.1155/2014/178410 |
_version_ | 1782320583017496576 |
---|---|
author | Giopanou, Ioanna Bravou, Vasiliki Papanastasopoulos, Panagiotis Lilis, Ioannis Aroukatos, Panagiotis Papachristou, Dionysios Kounelis, Sophia Papadaki, Helen |
author_facet | Giopanou, Ioanna Bravou, Vasiliki Papanastasopoulos, Panagiotis Lilis, Ioannis Aroukatos, Panagiotis Papachristou, Dionysios Kounelis, Sophia Papadaki, Helen |
author_sort | Giopanou, Ioanna |
collection | PubMed |
description | NF-κB signaling promotes cancer progression in a large number of malignancies. Metadherin, a coactivator of the NF-κB transcription complex, was recently identified to regulate different signaling pathways that are closely related to cancer. We assessed the immunohistochemical expression of p50, p65, and metadherin in 30 ovarian carcinomas, 15 borderline ovarian tumours, and 31 benign ovarian cystadenomas. Ovarian carcinomas exhibited significantly higher expression of all 3 markers compared to benign ovarian tumours. Borderline ovarian tumours demonstrated significantly higher expression for all 3 markers compared to benign cystadenomas. Ovarian carcinomas demonstrated significantly higher expression of p50 and metadherin compared to borderline ovarian tumours, whereas no significant difference was noted in p65 expression between ovarian carcinomas and borderline ovarian tumours. There was a strong correlation with the expression levels of p50, p65, and metadherin, whereas no correlation was observed with either grade or stage. Strong p50, p65, and metadherin expression was associated with a high probability to distinguish ovarian carcinomas over borderline and benign ovarian tumours, as well as borderline ovarian tumours over benign ovarian neoplasms. A gradual increase in the expression of these molecules is noted when moving across the spectrum of ovarian carcinogenesis, from borderline ovarian tumours to epithelial carcinomas. |
format | Online Article Text |
id | pubmed-4055019 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-40550192014-06-24 Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study Giopanou, Ioanna Bravou, Vasiliki Papanastasopoulos, Panagiotis Lilis, Ioannis Aroukatos, Panagiotis Papachristou, Dionysios Kounelis, Sophia Papadaki, Helen Biomed Res Int Research Article NF-κB signaling promotes cancer progression in a large number of malignancies. Metadherin, a coactivator of the NF-κB transcription complex, was recently identified to regulate different signaling pathways that are closely related to cancer. We assessed the immunohistochemical expression of p50, p65, and metadherin in 30 ovarian carcinomas, 15 borderline ovarian tumours, and 31 benign ovarian cystadenomas. Ovarian carcinomas exhibited significantly higher expression of all 3 markers compared to benign ovarian tumours. Borderline ovarian tumours demonstrated significantly higher expression for all 3 markers compared to benign cystadenomas. Ovarian carcinomas demonstrated significantly higher expression of p50 and metadherin compared to borderline ovarian tumours, whereas no significant difference was noted in p65 expression between ovarian carcinomas and borderline ovarian tumours. There was a strong correlation with the expression levels of p50, p65, and metadherin, whereas no correlation was observed with either grade or stage. Strong p50, p65, and metadherin expression was associated with a high probability to distinguish ovarian carcinomas over borderline and benign ovarian tumours, as well as borderline ovarian tumours over benign ovarian neoplasms. A gradual increase in the expression of these molecules is noted when moving across the spectrum of ovarian carcinogenesis, from borderline ovarian tumours to epithelial carcinomas. Hindawi Publishing Corporation 2014 2014-05-22 /pmc/articles/PMC4055019/ /pubmed/24963474 http://dx.doi.org/10.1155/2014/178410 Text en Copyright © 2014 Ioanna Giopanou et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Giopanou, Ioanna Bravou, Vasiliki Papanastasopoulos, Panagiotis Lilis, Ioannis Aroukatos, Panagiotis Papachristou, Dionysios Kounelis, Sophia Papadaki, Helen Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title | Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title_full | Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title_fullStr | Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title_full_unstemmed | Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title_short | Metadherin, p50, and p65 Expression in Epithelial Ovarian Neoplasms: An Immunohistochemical Study |
title_sort | metadherin, p50, and p65 expression in epithelial ovarian neoplasms: an immunohistochemical study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055019/ https://www.ncbi.nlm.nih.gov/pubmed/24963474 http://dx.doi.org/10.1155/2014/178410 |
work_keys_str_mv | AT giopanouioanna metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT bravouvasiliki metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT papanastasopoulospanagiotis metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT lilisioannis metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT aroukatospanagiotis metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT papachristoudionysios metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT kounelissophia metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy AT papadakihelen metadherinp50andp65expressioninepithelialovarianneoplasmsanimmunohistochemicalstudy |